Meeting
2019 Gastrointestinal Cancers Symposium
KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
Authors
You Yone
Charing Cross Hospital, London, Imperial College Healthcare NHS Trust, London, United Kingdom
You Yone , Mohammad Abdallah , Saad Sabih Tahir , Selim Cellek , Jufen Zhang , Yvonne Lester , Lauren Shillito , Jennifer Child , Lizzie Dawson , Bryan Singizi , Stephen Bustin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 536)
DOI
10.1200/JCO.2019.37.4_suppl.536
Abstract #
536
Poster Bd #
E19
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.
First Author: Xuefeng Fang
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz